Authors
Loading...
Recent updates reveal diverse treatment strategies for chronic lymphocytic leukemia, highlighting the role of venetoclax and minimal residual disease in therapy selection.
Kristen McClellan (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: